Member Info for SocialistB

On Tuesday, 31-12-2024, the last trading day of 2024, there was a RNS regarding the total amount of shares in existence.

Today, Thursday 2-1-2024, the first trading day of 2025, we have yet another non clinical RNS, this time about changing the secretary of the company.

I see it all as housekeeping RNS' that is lining up for significant news ahead.

Personally I do not hope for any significant news until next week, as I simply don't think the market is back, ready and up to full speed until then.

So, I suspect something is brewing.

January is going to be awesome

Happy New Year to all share holders and posters who genuinely wants HEMOGENYX to do well, for the benefit of all, Patients and shareholders alike.

Yesterday we had yet another RNS from HEMOGENYX and we have had plenty of them during December, have a look at Tillywiz's post from yesterday morning at 0732, where he mentions every single one released in December 2024.

Yesterday's RNS' was in my eyes just bit of housekeeping when they mention

"as at 31 December 2024 consists of 3,504,539 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 3,504,539."

To me that would seem to be rather unnecessary information to release unless something is brewing.

I think we might get an incredible start to 2025, not necessarily on the 2nd of January, but soon, none the less.

And that we might soon hear about various stakeholders owning above 3% as they invest in the company, hopefully at a premium.

And for me, a premium is in the 30 pounds region as I think new investors should pay above Prevail Partners investment (old money, 6 pence region) new money 24 pound region.

Less will most likely be the reality:-)

But, wouldn't it be an awesome start to 2025, if new investors was announced at a price in the region of 30 quid and with warrents at an even higher prize?

A man is allowed to dream, right?

So, no RNS first thing this morning.

In my book that is money saved, because in my view there is not an audience between Christmas and New Year.

So much better to come back to the market on Tuesday 7-1-2025, with excellent news that there has been a rush to sign up to trials over the festive season.

Why wait until Tuesday 7-1-2025, let people get back into the offices first and get good and proper ready for the new year.

I'll even go as far and say that I would to some degree be pleased even if it was announced that funding came with a discount, as long as we get enough to progress HEMO CAR-T and CBR.

Not my dream scenario, but an acceptable one.

But let's hope for funding at a premium, perhaps with warrents at a premium as a sweetener as well.

Happy New Year and hopefully a successful 2025 for Patients and investors, employees and Doctors, nurses as well, basically everyone involved in a positive role.

@Tillywhiz, I hope you'll get a full and speedy recovery.

And I'd like to second the last 2 paragraphs of your post.

And wish a Merry Christmas to every thoughtfull and sincerely shareholder that wish nothing but the best for Hemogenyx and the many people the company can hopefully help in the future.

Could future funding possibly come in the region of £24?

I admit it sounds crazy, but based on old money, before the consolidation, Prevail paid in the region of 6 pence, which is what £24 is equal to today. (or thereabout)

It would make sense from a certain point of view.

The new investors coming on board now know that their money will bring science out of the lab and into the real world. And they know it will not be cheap either, because it generally isn't in Pharma.

For that reason, they might be willing to pay a significant premium to ensure that good, decent funding is in place from the beginning, in the hope that it will create an ever-growing share price based on positive scientific news.

This will, in turn, minimise their dilution in the future.

From that point of view, paying a significant premium makes absolute sense.

But is the market willing to pay such a high premium?

I doubt it, as everyone wants their entry point as low as possible.

But in this case, I assume it is evident to professional investors that paying as little as possible won't work because that does not bring the science forward with the desired speed, if at all.

It is my understanding that Prevail does not typically invest as early as they did in HEMOGENYX.

Considering it was just in the 100s of thousands of pounds, they might be okay with new investors getting a lower entry point than they did.

As I recall it, Mr Sandler was ecstatic to have 60 million available to draw from once. That did not work out as beautifully as we all hoped for but look at what he and the team have managed to create on a shoestring since that credit facility went belly up.

Therefore, I dream of a total of 1 million shares issued to several investors at a premium to Prevail investment, but in new money.

That would settle all fears of funding for the foreseeable future, but it would still leave shares to be issued at higher prices as the hopefully good clinical data rolls in.

Here's to hoping that the unlikely will happen:-)

And much as I hate the thought of that, as I would like to participate in this journey, there is one thing I hate even more.

Selling for peanuts

@Dazpink

A major like Eli Lilly, GSK, Novartis or anyone else, take your pick, can at anytime come with an offer.

Anytime.

But they can only buy the company if we the shareholders sell it to them.

Decifering your post (maybe wrongly) to me it sounds like you want to sell up as long as there is a premium to today's price.

At a point where we maybe have only proven up HEMO CAR-T on a few patients. I think it will be unrealistic to expect much more from quarter 1 2025.

Definitely way before Hemogenyx have proven up CBR in clinical studies.

CDX, who knows when the news will arrive, probably first after HEMO CAR-T has been proven up (just a hunch)

The point is, selling HEMOGENYX will never be the best interest for us shareholders if the candidates work.

If our candidates work, I think we can one day match Eli Lilly and any of the other majors.

But it is not going to happen overnight and there will be hiccups along the way and mistakes will also be made.

Just like it has happened for any other major pharmaceutical company out there.

So what have changed for you in the last 11 days, since you wrote the following:

"Still have 2.6m, not sold any just keep building it up and the share price nosed dived. Happy to wait until late 2025 to decide what to do with them"

That was on 11-12-2024.

Since then we have had good news about a cooperation development with KURE.AI about ultrafast CAR-T Manufacturing on Thursday 19-12-2024 aiming to reduce the manufacturing time to 1 day.

And prior to that, on the 6-12-2024 we had the MAGNIFICENT update on CBR Macrophage delivery.

Science wise everything is going very well indeed.

HEMOGENYX cannot control the market, only navigate it.

And there has been some rough seas, but the BOD has at all time managed to keep the ship intact and with provisions.

And now it seems like the course is set for new and better harbour then the London market. ( Might even lead to a dual listing)

So, why on earth, at this critical point in the company's history, right on the threshold of going clinical and with a BOD that has proven that they can navigate the rough seas and everything that the market has thrown at the company, do you desire a takeover for peanuts.

Because selling HEMOGENYX at this stage if the candidates work will be peanuts, no matter what comes on the table.

Eli Lilly was founded in 1876 and now has a market cap of over 728 Billion dollars.

It will not take HEMOGENYX a 128 years to reach a market cap in that region (not saying that we can match or beat it) if CBR delivers as significantly as I believe and hope it will.

A potential cure for many if not all viruses.

Works on some bacteria as well by the sound of it.

Shows great prospect in regard to some solid cancers.

The future is bright.

And maybe for that very reason we should expect an offer one day.

And much as I hate the thought of that, as I would like this journey, there is one thing I h

@Hulver

Thanks for the posts and links yesterday.

Sorry, I did respond sooner, I first saw the "SB" this morning.

Yesterday, I was as well looking into KURE.AI but did not find much.

They do not have a website. ( Or I have not been able to find it)

The website is under construction.

But I found that David Wald graduated from Cornell University in 1997.

And both Dr. Sandler and Dr. van Besien have association to Cornell.

The next sweatshirt I'm buying with an American university/college logo is definitely going to be CORNELL:-)

I have not managed to find out exactly what it is KURE.AI is doing

Is it purely a software solution figuring out what protein goes where to optimise the uptake ( simplyfied) or are they collaborating with robot manufactures as well as I doubt they are producing machinery themselves.

According to an AI site it works as follows:

Kure.ai’s Ultrafast Manufacturing Technology

Kure.ai’s ultrafast manufacturing technology aims to streamline and accelerate this complex process while maintaining the therapeutic efficacy of the CAR-T cells. Here’s how it works:

Integration of Advanced Automation: Kure.ai employs advanced automation techniques throughout the manufacturing process. This includes robotic systems that can handle multiple tasks simultaneously, such as cell isolation, transduction (the process of introducing genetic material into cells), and expansion. By automating these steps, Kure.ai significantly reduces human error and increases efficiency.

Optimized Transduction Process: One of the key innovations in Kure.ai’s technology is its optimized transduction method. This involves using lentiviral vectors to introduce the CAR gene into T-cells more effectively than traditional methods. The optimization ensures a higher transduction efficiency, meaning more T-cells are successfully modified in a shorter time frame.

Rapid Expansion Techniques: After T-cells are modified with the CAR gene, they need to be expanded to sufficient numbers for therapeutic use. Kure.ai utilizes specialized culture media and bioreactor systems designed for rapid cell growth. These systems provide optimal conditions for T-cell proliferation while minimizing contamination risks.

Real-Time Monitoring and Quality Control: Throughout the manufacturing process, Kure.ai implements real-time monitoring systems that track various parameters such as cell viability, growth rates, and vector copy number (VCN). This data allows for immediate adjustments to be made during production to ensure that quality standards are met without delays.

In Vitro Testing for Potency Verification: Before the final product is released for clinical use, Kure.ai conducts rigorous in vitro testing on the manufactured CAR-T cells to verify their potency and functionality. This step is crucial as it ensures that the modified T-cells can effectively recognize and kill cancer cells once reintroduced into patients.

Customization for Specific Therapies: Kure.ai’s technology is adaptable; it can be customized according to specific requirements of different CAR-T therapies being developed by partners like Hemogenyx Pharmaceuticals. This flexibility allows for tailored solutions that meet unique therapeutic needs while still benefiting from ultrafast production timelines.

Licensing Opportunities: If successful in their collaboration with Hemogenyx Pharmaceuticals, there may be opportunities for licensing Kure’s ultrafast manufacturing technology for broader applications in clinical trials or commercial production.

By integrating these advanced methodologies into CAR-T cell production, Kure.ai aims not only to reduce manufacturing times significantly but also to enhance overall product quality and consistency—ultimately improving patient access to life-

@Barbershop

Had we gotten some funds it MIGHT, just MIGHT have prevented some of the shenanigans.

MAYBE, just MAYBE.

Always easy to conclude or wonder with the benefit of hindsight.

Don't get me wrong, I think it is a very conclusion you have arrived at and the best answer I can come up with are that either the process was to cumbersome at the time for the company.

Or that there were severe restrictions attached to the money, that would potentially cause trouble at some point.

But that is also just guess work, in this case from my side:-)

@ Hulver, Thank you for the link and your suggestions.

I do not recall having read that article in the past, so thank you very much for uploading it (Maybe again:-)

As I recall it, Dr Sandler did his ground breaking work with HU-PEC while at Weill Cornell Medical College in New York, where Dr. Koen van Besien is a Professor of Medicine at the time; the article was written (and maybe still is; I have not researched it)

It is also interesting to see that "Dr. van Besien has served on the faculty of MD Anderson Cancer Center in Houston", where our trial will start anytime soon. 

HEMOGENYX has indeed understood to engage with the right people regarding science.

I mean, it was terrific to hear Dr. Sandler's pride in his voice yesterday when he spoke about how the team had overcome a complex problem in CBR technology through team effort on a limited budget.

So, I hope that today's antics do not negatively affect the funds that HEMOGENYX can raise.

Equally, I hope that all LTHs have learned that it is dangerous to activate STOP LOSS at this critical stage in the company's development and when there are a significant number of shorts open.

Today, it has been proven beyond a shadow of a doubt that the people behind the shorts can and will drive the price lower.

It is not easy to run a company when fighting an invincible enemy.

Let's hope we soon hear from Prevail and potential partners they have teamed up with regarding funding HEMOGENYX for the foreseeable future.

In yesterday's interview, Dr Sandler mentioned the possibility that Hemogenyx could participate in developing a process to manufacture the cells in a day, which would significantly lower the cost.

He mentioned around 5.20 minutes that several companies and research groups are dealing with this issue.

So that raises who these companies and institutions can be.

Some AI research shows the following possibilities:

University Hospitals (UH) Seidman Cancer Center: In collaboration with a biotech start-up, they have developed a new manufacturing process that could reduce the time to manufacture CAR-T therapies to approximately 24 hours.

Blue Matter Consulting: They have identified several approaches to improve CAR-T manufacturing efficiency, including "rapid manufacturing" techniques that aim to reduce overall processing time from several weeks down to just one or two days.

McKinsey & Company: They have highlighted efforts to optimize autologous CAR-T therapies and explore new manufacturing techniques to shorten the innovation cycle time.

Any other suggestions?

This company has a tremendous possibility to move forward when we get some resources.

Should I say thank you, and if so, whom should I thank?

I think the 25 percent fall today was the result of a deliberate attack.

To what end, I am unsure at the moment.

Time might give a clue.

Has shorts been closed?

Is the incoming funds attached to the share price in the previous trading days? (Clarification, it's me who expects incoming funds, nothing has been guaranteed)

If it was just a deliberate attempt to close shorts and no further damage was done to the price at which we can raise funding in the future, I guess I should thank you for creating an opportunity for me to buy cheaper shares.

If on the other hand, this action has had a detrimental negative effect on the funds that HEMO can raise to conduct further research, we'll do I really have spell what I think of people like that?

8.25 minutes - There is significant interest in HEMO CAR-T, leading to the potential opening of a new clinical site at a prominent hospital on the East Coast.

Ten minutes in, it's clear that CBR has made a huge breakthrough, and it has happened on meagre resources.

Now we just need news on funding and a few signatures and then we are ready to go.

@MarcoBerlin

Thanks for the link.

I really love this bit:

"CBRs are modular synthetic receptors that are expressed on the surface of immune cells and can be rapidly reconfigured to attack almost any pathogen: virus, bacteria, or malignant cells; specifically, on macrophages in the upper respiratory tract to fight airborne viral infections."

So there it is CBR also works against bacteria.

I hope that over time, with the extra funding that I think will soon become available, Hemogenyx will be able to advance CBR from working "specifically on macrophages in the upper respiratory tract" to work on all bacteria.

It would be awesome if it could compete with antibiotics and even better really deal with sepsis.

It is amazing what the scientists have managed to do so far on what can rightly be considered a shoestring budget in medical research.

Imagine what they can do and how much faster they can progress the products when they get decent funds to work with.

I doubt we will get all the funds needed in one go, but I expect that as the various candidates hopefully shows positive progress there will be a queue of investors willing to invest in the candidates.

And talking about candidates, if this stuff works, it should be worthy of a Nobel Prize sometime in the future and it is nice to see the last 3 lines of credit sharing:

"R. Ben Jehuda1,*; M.R. Haugbro1,*; S.K. Dhingra1,*; A. Babuji1; T. Wasiliewska1; K.T. Joseph1; D.S. Wang1; E. Shrestha1; V.M. Sandler1;

1Hemogenyx Pharmaceuticals LLC, New York, NY.

*These authors equally contributed to the study"

I love when credit is given where credit is due and this seems to be very much a team effort.

Go team HEMO

@TuckShopTom

Great attitude, being happy to have helped people.

Because if the various candidates works, you have even though the money did not go to Hemogenyx directly, but you brought liquidity to the market and that is never a bad thing.

Will you ever get your money back?

I most certainly think you will, but be prepared it will take some time.

It looks like you'll need 28 Pounds to get a bit of a profit.

I believe we will go much higher then that in the years to come.

The shares are still incredible cheap.

Just 5% more expensive then yesterday when you ignore the consolidation.

And the prospects have never been better (assuming funding is right around the corner)

I reckon that if you were to invest another 1000 Pounds now at 4.20 pounds, then you could lower your average to less then 8 quid.

This is not investment advise, everything can still go wrong and the heavens can also come crashing down etc.

It is nothing more then pocket calculation given to someone with a delightful attitude who I for that very reason wish all the best with their investment.

As the share price ended on 1 Pence yesterday I expected the share to start at 4 Pounds this morning.

It's now trading at 4.20 Pounds.

5% up just on just being consolidated, out of the penny state and into the Pounds state.

Now we awaite news regarding:

Investment through sale of shares (Dilution)

Possible non dilution funding, I.e grants

HEMO CAR-T

CDX

CBR

Ability to modify white blood cells.

I expect/hope to hear about HEMO CAR-T and some sort of funding within a week.

And news regarding CDX, CBR and modification of white blood cells throughout 2025.

Especially CBR, which I for a long time has seen as the crown jewel, but the modification of white blood cells is now also really getting my blood flowing (pun intended)

Will we get an RNS today or will they wait til next week, giving the various brokers time to sort out all the issues that has come as a consequence of the consolidation.

SPELLING MISTAKE.

However, I am confident we will soon hear possitive news and the share price will SHOOT up.

Here's to hoping.

End price today seems to be 1 Pence, for that reason I expect the consolidated shares to be 4 Pounds tomorrow.

But what price is the first share going to be sold at tomorrow morning.

Will it be sold at 3.80 or less?

Will it be sold at a premium to the expected 4 pounds?

I guess it all depends on wether we get funding news prior to the shares hitting the market.

And the old adage of supply and demand.

If, tomorrow when the shares can be traded there is a higher demand then supply, we will see a rising share price.

If on the other hand there is a vacuum of news and demand for the shares, then there is suddenly a long possible fall.

However, I am confident we will soon hear possitive news and the share price will shut up.

Here's to hoping.

@Jonnyr

Point taken.

So the most likely possitive news we are to receive this year is regarding funding.

Cheers to a fantastic 2025 that is very likely to bring news regarding.

HEMO CAR-T

CDX

CBR

WHITE BLOOD CELLS and the possible modifications.